首页> 外文期刊>American Journal of Clinical and Experimental Medicine >Prevalence of Acridine Immunization to Subsaharians Africans Blood Donors
【24h】

Prevalence of Acridine Immunization to Subsaharians Africans Blood Donors

机译:吖啶免疫移植到子地区非洲人献血者

获取原文
       

摘要

To conduct a study project on the inactivation of pathogens in whole blood using acridine derivatives in Africa, in order to prevent the transmission of pathogens, it is important to look for possible immunization to acridine in the blood donor population. It is therefore important to undertake an estimate of the prevalence in the sub-Saharan population in order to guide the design of the clinical study that will use the INTERCEPT Red Blood System procedure on whole blood for transfusion. to define the starting point in the evaluation of the immunological safety and transfusion safety of the product treated by this process. The objective of this study is to determine the prevalence of AAA among blood donors in sub-Saharan Africa. We conducted a multicenter prospective descriptive study of 902 blood donors collected in Cote d'Ivoire, Benin and Cameroon over the period from June 2015 to January 2017. Blood samples were collected from voluntary blood donors, of any sex, aged between 18 and 65, having given their consent for the study and having participated in the medical consultation for the donation of blood. The samples were analyzed according to the technique of the RAI gel card of the company BIORAD after centrifugation and incubation using test red cells treated with S-303 and glutathione. In the case of positive RAI results, to confirm the presence of anti-acridine, the donor plasma should be incubated with S-300. S-300 is a degradation product of S-303. The donor serum and S-300 are then incubated with the same red test cells. S-300 binds to the antibody and produces a negative result in the gel map in the presence of anti-acridin antibodies. Of the 903 samples tested both at the Abidjan laboratory in Cote D'Ivoire and at the Frankfurt laboratory, we found 1 positive sample and 8 reactive samples (positive for anti-erythrocyte antibodies). Positive donor plasma was incubated with S-300 which is the degradation product of S-303. The result is always positive, whereas according to the instructions of the reference laboratory of Frankfurt, it should be negative in case of presence of Locustacan. The results on AAA testing among 903 donors in three sub-Saharan countries show the absence of AAA in the sample of subjects included in the study according to the hypothesis emitted from this study. This opens the door to the prospect of conducting a clinical study on the inactivation of pathogens by acridine derivatives.
机译:在非洲使用吖啶衍生物的全血液中的病原体灭活研究项目,以防止病原体的传播,重要的是寻找可能免疫血液供体群中吖的疫苗。因此,重要的是对撒哈拉群人群的流行进行估计,以指导将使用截止红血系统程序对全血来输血的临床研究的设计。为了定义通过该方法处理的产品的免疫安全和输血安全性评估的起点。本研究的目的是确定撒哈拉以南非洲献血者中AAA的患病率。我们在2015年6月至2017年1月至2017年1月,在Cote d'Ivoire,贝宁和喀麦隆收集的902份献血者的多中心预期描述性研究。从自愿献血者,任何性别,18至65岁的血液样本收集血液样本,鉴于他们同意研究并参加了捐赠血液的医疗咨询。通过用S-303和谷胱甘肽处理的试验红细胞进行离心和孵育后,根据公司BiORAD的RAI凝胶卡的技术进行分析样品。在阳性rai结果的情况下,为了确认抗吖啶的存在,应与S-300孵育供体血浆。 S-300是S-303的降解产物。然后将供体血清和S-300与相同的红色测试细胞一起温育。 S-300与抗体结合,在抗吖啶型抗体存在下产生凝胶图的阴性结果。在Abidjan实验室在Cote D'Ivoire和法兰克福实验室测试的903个样本中,我们发现了1个阳性样品和8个反应性样品(抗红细胞抗体阳性)。将阳性供体等离子体与S-300一起温育,这是S-303的降解产物。结果总是积极的,而根据法兰克福的参考实验室的说明,如果出现洛杉卡兰的情况下,它应该是负面的。在三个撒哈拉国家的903个捐助者中进行AAA测试的结果表明,根据本研究发出的假设,在研究中包含的受试者样本中没有AAA。这为通过吖啶衍生物进行临床研究进行临床研究的前景开辟了门。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号